Suppr超能文献

胶质母细胞瘤中 MSI2-TGF-β/TGF-β R1/SMAD3 正反馈调控。

MSI2-TGF-β/TGF-β R1/SMAD3 positive feedback regulation in glioblastoma.

机构信息

Department of Neurosurgery, Collaborative Innovation Center for Cancer Medicine, Xiangya Hospital, Central South University, Xiangya Road 87, Changsha, 410008, Hunan, People's Republic of China.

Cancer Research Institute, Collaborative Innovation Center for Cancer Medicine, The Key Laboratory for Carcinogenesis of Chinese Ministry of Health and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, School of Basic Medical Science, Central South University, Changsha, Hunan, People's Republic of China.

出版信息

Cancer Chemother Pharmacol. 2019 Aug;84(2):415-425. doi: 10.1007/s00280-019-03892-5. Epub 2019 Jun 27.

Abstract

PURPOSE

Glioblastoma is the most malignant glioma tumors with inevitable relapse and resistance to chemotherapy; however, the mechanisms driving chemoresistance remain to be fully elucidated. This study is to explore the molecular and cellular mechanisms involving in the chemoresistance of glioblastoma.

METHODS

The expression of musashi (MSI) RNA-binding protein in the tumor tissues and cells of glioblastoma was measured. The effects of MSI2 in epithelial-to-mesenchymal transition (EMT), resistance to temozolomide (TMZ), tumor cell invasion, migration, and proliferation and associated signaling were evaluated.

RESULTS

High MSI2 expression was observed in the glioblastoma tissues. Silencing or overexpression of MSI2 significantly affected tumor cells invasion, migration, and proliferation. Silencing of MSI2 expression significantly inhibited O-methylguanine-DNA methyltransferase (MGMT) expression and tumor growth, and reversed resistance to TMZ in xenograft tumor models. MSI2 expression regulated EMT through activating the transcription factors Snail and the TGFβ R1/SMAD3 signaling.

CONCLUSIONS

Our study demonstrated a positive feedback loop of MSI2-TGFβ/SMAD3 signaling which activates the EMT and MGMT which may contribute to chemoresistance in glioblastoma. This study also highlights that MSI2 could be a new target for the therapy of glioblastoma.

摘要

目的

胶质母细胞瘤是最恶性的神经胶质瘤肿瘤,不可避免地会复发和对化疗产生耐药性;然而,导致化疗耐药的机制仍有待充分阐明。本研究旨在探讨涉及胶质母细胞瘤化疗耐药的分子和细胞机制。

方法

测量胶质母细胞瘤肿瘤组织和细胞中 musashi(MSI)RNA 结合蛋白的表达。评估 MSI2 在上皮间质转化(EMT)、对替莫唑胺(TMZ)的耐药性、肿瘤细胞侵袭、迁移和增殖以及相关信号中的作用。

结果

观察到胶质母细胞瘤组织中 MSI2 表达较高。沉默或过表达 MSI2 显著影响肿瘤细胞的侵袭、迁移和增殖。沉默 MSI2 表达显著抑制 O-甲基鸟嘌呤-DNA 甲基转移酶(MGMT)表达和肿瘤生长,并逆转异种移植肿瘤模型对 TMZ 的耐药性。MSI2 表达通过激活转录因子 Snail 和 TGFβ R1/SMAD3 信号转导来调节 EMT。

结论

我们的研究表明,MSI2-TGFβ/SMAD3 信号的正反馈回路激活 EMT 和 MGMT,这可能导致胶质母细胞瘤的化疗耐药性。本研究还强调,MSI2 可能成为胶质母细胞瘤治疗的新靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验